title: [New therapeutic strategies in ANCA-associated systemic vasculitis].
abstract: High-dose corticosteroids in combination with cytotoxic drugs are universally accepted as the initial treatment in ANCA-associated vasculitis. Cyclophosphamide is the most effective cytotoxic drug and is used in more severe cases. Because of short- and long-term side-effects, novel therapies have been tested. New prospects for the treatment of vasculitis include sequential chemotherapy (e.g. cyclophosphamide followed by azathioprine or cyclophosphamide followed by methotrexate) and/or novel immunosuppressive agents (e.g. mycophenolate mofetil, anti-TNF-alpha).
authors.affiliation: Service d'immunologie et allergie, CHUV, Rue du Bugnon 46, 1011 Lausanne. floriana.lurati@chuv.hospvd.ch
authors.forename: F Lurati
authors.initials: FL
authors.lastname: Ruiz
authors.forename: P A
authors.initials: PA
authors.lastname: Bart
mesh_terms: D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D001379:Azathioprine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D019268:Antibodies, Antineutrophil Cytoplasmic; D007166:Immunosuppressive Agents; D001379:Azathioprine